Histoplasmosis

Up-to-Date Evidence-Based Approach to Diagnosis and Management

Chadi Hage, Marwan M. Azar, Nathan Bahr, James Loyd, L. Joseph Wheat

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Histoplasmosis is the most common endemic mycosis in the North America, Central America, and many countries of South America and also occurs in China, India, Southeast Asia, Africa, Australia, and Europe. Clinical syndromes are not specific and histoplasmosis often is overlooked in the evaluation of patients with community-acquired pneumonia, chronic cavitary pneumonia resembling tuberculosis or anaerobic infection, granulomatous inflammatory diseases such as sarcoidosis or Crohn disease, and malignancy. The diagnosis depends on understanding the geographic distribution, common clinical presentations, and tests used for diagnosis of histoplasmosis. While histoplasmosis resolves without treatment in most patients, treatment is indicated in all immunocompromised patients and those with progressive disseminated disease or chronic pulmonary disease. Treatment is appropriate in most patients with acute pulmonary disease but rarely in those with other pulmonary or mediastinal manifestations. The preferred agents include liposomal amphotericin B for more severe cases and itraconazole for milder cases and step-down therapy following response to amphotericin B.

Original languageEnglish
Pages (from-to)729-745
Number of pages17
JournalSeminars in Respiratory and Critical Care Medicine
Volume36
Issue number5
DOIs
StatePublished - Oct 25 2015

Fingerprint

Histoplasmosis
Lung Diseases
Pneumonia
Hospital Distribution Systems
Central America
Southeastern Asia
Itraconazole
Mycoses
South America
Immunocompromised Host
Amphotericin B
Acute Disease
Therapeutics
Sarcoidosis
North America
Crohn Disease
India
China
Tuberculosis
Chronic Disease

Keywords

  • antibody
  • antigen
  • diagnosis
  • disseminated
  • epidemiology
  • histoplasmosis
  • pneumonia
  • treatment

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Histoplasmosis : Up-to-Date Evidence-Based Approach to Diagnosis and Management. / Hage, Chadi; Azar, Marwan M.; Bahr, Nathan; Loyd, James; Wheat, L. Joseph.

In: Seminars in Respiratory and Critical Care Medicine, Vol. 36, No. 5, 25.10.2015, p. 729-745.

Research output: Contribution to journalArticle

Hage, Chadi ; Azar, Marwan M. ; Bahr, Nathan ; Loyd, James ; Wheat, L. Joseph. / Histoplasmosis : Up-to-Date Evidence-Based Approach to Diagnosis and Management. In: Seminars in Respiratory and Critical Care Medicine. 2015 ; Vol. 36, No. 5. pp. 729-745.
@article{68a4eb6247b4424fb6ab0a597556c8bd,
title = "Histoplasmosis: Up-to-Date Evidence-Based Approach to Diagnosis and Management",
abstract = "Histoplasmosis is the most common endemic mycosis in the North America, Central America, and many countries of South America and also occurs in China, India, Southeast Asia, Africa, Australia, and Europe. Clinical syndromes are not specific and histoplasmosis often is overlooked in the evaluation of patients with community-acquired pneumonia, chronic cavitary pneumonia resembling tuberculosis or anaerobic infection, granulomatous inflammatory diseases such as sarcoidosis or Crohn disease, and malignancy. The diagnosis depends on understanding the geographic distribution, common clinical presentations, and tests used for diagnosis of histoplasmosis. While histoplasmosis resolves without treatment in most patients, treatment is indicated in all immunocompromised patients and those with progressive disseminated disease or chronic pulmonary disease. Treatment is appropriate in most patients with acute pulmonary disease but rarely in those with other pulmonary or mediastinal manifestations. The preferred agents include liposomal amphotericin B for more severe cases and itraconazole for milder cases and step-down therapy following response to amphotericin B.",
keywords = "antibody, antigen, diagnosis, disseminated, epidemiology, histoplasmosis, pneumonia, treatment",
author = "Chadi Hage and Azar, {Marwan M.} and Nathan Bahr and James Loyd and Wheat, {L. Joseph}",
year = "2015",
month = "10",
day = "25",
doi = "10.1055/s-0035-1562899",
language = "English",
volume = "36",
pages = "729--745",
journal = "Seminars in Respiratory and Critical Care Medicine",
issn = "1069-3424",
publisher = "Thieme Medical Publishers",
number = "5",

}

TY - JOUR

T1 - Histoplasmosis

T2 - Up-to-Date Evidence-Based Approach to Diagnosis and Management

AU - Hage, Chadi

AU - Azar, Marwan M.

AU - Bahr, Nathan

AU - Loyd, James

AU - Wheat, L. Joseph

PY - 2015/10/25

Y1 - 2015/10/25

N2 - Histoplasmosis is the most common endemic mycosis in the North America, Central America, and many countries of South America and also occurs in China, India, Southeast Asia, Africa, Australia, and Europe. Clinical syndromes are not specific and histoplasmosis often is overlooked in the evaluation of patients with community-acquired pneumonia, chronic cavitary pneumonia resembling tuberculosis or anaerobic infection, granulomatous inflammatory diseases such as sarcoidosis or Crohn disease, and malignancy. The diagnosis depends on understanding the geographic distribution, common clinical presentations, and tests used for diagnosis of histoplasmosis. While histoplasmosis resolves without treatment in most patients, treatment is indicated in all immunocompromised patients and those with progressive disseminated disease or chronic pulmonary disease. Treatment is appropriate in most patients with acute pulmonary disease but rarely in those with other pulmonary or mediastinal manifestations. The preferred agents include liposomal amphotericin B for more severe cases and itraconazole for milder cases and step-down therapy following response to amphotericin B.

AB - Histoplasmosis is the most common endemic mycosis in the North America, Central America, and many countries of South America and also occurs in China, India, Southeast Asia, Africa, Australia, and Europe. Clinical syndromes are not specific and histoplasmosis often is overlooked in the evaluation of patients with community-acquired pneumonia, chronic cavitary pneumonia resembling tuberculosis or anaerobic infection, granulomatous inflammatory diseases such as sarcoidosis or Crohn disease, and malignancy. The diagnosis depends on understanding the geographic distribution, common clinical presentations, and tests used for diagnosis of histoplasmosis. While histoplasmosis resolves without treatment in most patients, treatment is indicated in all immunocompromised patients and those with progressive disseminated disease or chronic pulmonary disease. Treatment is appropriate in most patients with acute pulmonary disease but rarely in those with other pulmonary or mediastinal manifestations. The preferred agents include liposomal amphotericin B for more severe cases and itraconazole for milder cases and step-down therapy following response to amphotericin B.

KW - antibody

KW - antigen

KW - diagnosis

KW - disseminated

KW - epidemiology

KW - histoplasmosis

KW - pneumonia

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=84942255046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942255046&partnerID=8YFLogxK

U2 - 10.1055/s-0035-1562899

DO - 10.1055/s-0035-1562899

M3 - Article

VL - 36

SP - 729

EP - 745

JO - Seminars in Respiratory and Critical Care Medicine

JF - Seminars in Respiratory and Critical Care Medicine

SN - 1069-3424

IS - 5

ER -